Switch for osteoporosis and obesity
German researchers have found a molecular switch that determines whether mesenchymal fibroblasts differentiate into fat- or bone-forming cells opening the avenue to modulation of the processes.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2154 entries already.
Entries by Thomas Gabrielczyk
Roche presents biomarker test to identify NSCLC responders to Tecentriq
Researchers at Roche’s US arms Genentech and Foundation Medicine Inc. (FMI) presented a liquid biopsy test that can be used to identify NSCLC patients who respond to Roche’s PD-L1 blocker Tecentriq earlier than to FMI’s tissue based tumour mutation burden (TMB) assay.
Boehringer Ingelheim starts gene therapy collaboration for cystic fibrosis
German pharma company and CDMO Boehringer Ingelheim (BI) steps into the lucrative field of gene therapy. Together with the UK Cystic Fibrosis Gene Therapy Consortium (GTC), BI aims at developing replacement therapies compensating for mutations that lead to cystic fibrosis.
Arix Bioscience acquires 11% stake in Phamaxis Ltd.
An investor consortium led by British Arix Bioscience plc has put £13.4m into the Australian Pharmaxis Ltd, which develops fibrosis inhibitors based on its amine oxidase discovery platform.
Nanobots: Fiction becoming reality
Once confined to speculative and science fiction, miniature micro- or nanobots targeting pathogens or conditions directly have now become reality in research labs worldwide. But to enter clinical trials, scientists still have to overcome two major hurdles – visualising the tiny machines inside the body, and preventing a potential immune response.
Kick Off Vetter’s New Innovation Challenge
Vetter strikes out on new pathways to further develop the injection process.
CDMO launches the Vetter Open Innovation Challenge under the slogan Injection 2.0′
Crowdfunding goes blockchain
Spanish Capital Cell continues to be a pioneer in the health crowdfunding scene and launched a new self-funding fundraising round to create the first ICO marketplace for health via Blockchain.
Determined to reduce the risk of bleeds
Analysts say Roche’s bispecific antibody Hemlibra will rock the US$15bn haemophilia A market, given that it may circumvent therapy resistance that affects the 30% of patients who form antibodies against recombinant factor VIII products. European Biotechnology spoke with Dr. Gallia Levy, Associate Group Medical Director at Roche, who led clinical development of Hemlibra.
User-driven early certainty: EPO steps back
It was too good to be true. Following harsh criticism from industry, the European Patent Office (EPO) drafted a widely applauded proposal to allow exemptions to its Early Certainty Initiative in Examination. One month later, the EPO withdrew UDEC following a recommendation from Business Europe – the only business association sitting next to decision-makers in the EPO’s Administrative Council – not to bring UDEC into force in July.
A match made in Scandinavia
Two listed Scandinavian biotech companies are about to merge into one. Medical Prognosis Institute A/S (Nasdaq First North Stockholm) in Denmark and Oncology Venture Sweden AB (Aktie Torget) in Sweden aim to create what they call a one-stop-shop for personalised cancer treatments.